SNPMiner Trials (Home Page)
Report for Clinical Trial NCT04042558
Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene
The objective of this study is to assess the efficacy of the combination of Platinum
(carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage
IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations
following targeted therapies.
NCT04042558 NSCLC Stage IIIB NSCLC Stage IV EGFR Gene Mutation ALK Gene Rearrangement Positive ROS1 Gene Mutation
2 Interventions
Name: Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
Description: 4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles
Type: Drug
Group Labels: 1 Cohort with Bevacizumab
Name: Carboplatin + Pemetrexed + Atezolizumab
Description: Carboplatin + Pemetrexed + Atezolizumab
Type: Drug
Group Labels: 1 Cohort without Bevacizumab
Primary Outcomes
Measure: Objective response rate (ORR) according to RECIST 1.1 Time: After the end of 4 cycles (15 weeks)
Secondary Outcomes
Measure: The progression-free survival (PFS) Time: 1 year
Measure: The overall survival Time: 1 year
Measure: The duration of response Time: 1 year
Purpose: Treatment
Allocation: Non-Randomized
Parallel Assignment
There is one SNP
SNPs
After a first line of treatment with a TKI, most
patients progress and are eligible according to the mechanism of progression to a TKI of 3rd
generation in case of T790M resistance or chemotherapy. --- T790M ---